Edwards Lifesciences, a global leader in patient-focused medical innovations for structural heart disease, reported third-quarter financial results that exceeded internal expectations and prompted the company to raise its full-year guidance for the third time in 2026. The Irvine, California-based medical technology giant saw its total sales climb to $1.72 billion for the quarter, representing a 10.5% increase year-over-year. This growth was driven primarily by the continued dominance of its Transcatheter Aortic Valve Replacement (TAVR) portfolio and a significant surge in its Transcatheter Mitral and Tricuspid Therapies (TMTT) segment.
As the healthcare industry continues to navigate the post-pandemic landscape, Edwards Lifesciences has demonstrated a robust recovery from previous years of stagnant growth caused by hospital capacity constraints and staffing shortages. The latest financial data suggests a stabilization of the market, with procedure volumes returning to a steady, upward trajectory. Executives pointed to a combination of clinical breakthroughs, regulatory wins, and expanded insurance coverage as the primary catalysts for the company’s optimistic outlook for the remainder of 2026 and beyond.
Financial Performance Breakdown
The third quarter of 2026 served as a testament to the durability of Edwards’ core business units. The TAVR segment, which remains the company’s largest revenue generator, brought in $1.24 billion, an 8% increase compared to the same period in the previous year. While TAVR has historically been the flagship of the company, the TMTT segment emerged as a high-growth powerhouse during this quarter. Adjusted TMTT sales reached $207 million, marking a staggering 44% increase year-over-year.
The company’s overall sales growth of 10.5% reflects a strengthening demand for minimally invasive heart valve procedures. In light of these figures, Edwards Lifesciences raised its 2026 sales growth forecast to approximately 11.5% on a constant currency basis, moving up from its previous projection of 10% to 11%. Additionally, the company narrowed and boosted its outlook for the TMTT business, now expecting annual sales in that category to fall between $780 million and $790 million, a notable jump from the prior range of $760 million to $780 million.
This financial momentum is particularly significant given the competitive pressures in the medtech space. Edwards has successfully maintained its market share and even realized modest gains in international markets, partially due to strategic shifts by competitors. For instance, the exit of Boston Scientific from certain markets outside the United States has allowed Edwards to capture a larger portion of the global TAVR demand.
Clinical Breakthroughs: The PROGRESS Trial and Moderate AS
A major highlight of the third quarter was the presentation of data from the PROGRESS trial at the Transcatheter Cardiovascular Therapeutics (TCT) conference. The study focused on the use of Edwards’ Sapien 3 TAVR device in patients with moderate aortic stenosis (AS) who also exhibit at-risk clinical features. Traditionally, patients with moderate AS are managed through "watchful waiting" or clinical surveillance, with intervention only occurring once the disease progresses to a severe stage.
The PROGRESS trial results demonstrated that early intervention with the Sapien 3 TAVR device was superior to the standard-of-care clinical surveillance. CEO Bernard Zovighian described the findings as a "turning point" for the cardiology community. By intervening before the disease reaches a critical state, clinicians can prevent significant health declines, irreversible heart muscle damage, and heart failure.
Zovighian noted that these findings challenge the long-standing medical assumption that moderate AS patients are best served by passive management. The evidence suggests that a proactive approach can drastically improve long-term patient outcomes, effectively expanding the potential patient population for TAVR procedures. This shift from reactive to proactive disease management is expected to be a primary driver of volume growth for Edwards in the coming years.
Regulatory Milestones and Medicare Coverage Expansion
In addition to positive clinical data, Edwards Lifesciences has benefited from significant regulatory and reimbursement shifts in the United States. During the third quarter, the Centers for Medicare and Medicaid Services (CMS) released a final national coverage determination (NCD) for TAVR. This updated policy is a critical step toward increasing patient access, as it extends Medicare coverage to patients with severe aortic stenosis who are asymptomatic.
The CMS decision follows the success of the EARLY TAVR study, which provided the clinical foundation for the Food and Drug Administration (FDA) to grant Edwards an expanded indication for the Sapien 3 valve in April 2025. This approval allowed for the treatment of severe AS patients before they begin to show physical symptoms of the disease, such as chest pain or shortness of breath.
By securing both FDA approval and CMS reimbursement for asymptomatic patients, Edwards has effectively removed the major barriers to treatment for a significant demographic. "Putting it all together, there is robust evidence and emerging indications validating the patient benefits of proactive disease management," Zovighian said during the earnings call. He expressed reinforced confidence in the durable mid- to high-single-digit growth of the Sapien platform over the long term.
The Rapid Expansion of TMTT
While TAVR remains the foundation of Edwards’ revenue, the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment is rapidly becoming a vital pillar of the company’s growth strategy. The 44% increase in sales this quarter highlights the increasing adoption of the Pascal and Evoque systems. The Evoque tricuspid valve replacement system, in particular, has seen strong uptake as the first transcatheter therapy of its kind to receive FDA approval for the treatment of tricuspid regurgitation.
The mitral and tricuspid markets represent a massive underpenetrated opportunity. Unlike the aortic valve market, which has seen TAVR become a standard of care over the last decade, the mitral and tricuspid spaces are still in the early stages of adoption. Edwards’ investment in these therapies is beginning to pay off as clinical data continues to support the efficacy of transcatheter repair and replacement options for patients who are often too frail for open-heart surgery.
Analysts have noted that the TMTT segment provides Edwards with a diversified growth profile. As the TAVR market matures, TMTT offers a "second act" that could sustain double-digit growth for the company well into the 2030s.
Analyst Perspectives and Market Stability
Financial analysts have reacted positively to Edwards’ third-quarter performance, noting that the company appears to have moved past the operational hurdles that plagued the industry in 2023 and 2024. Marie Thibault, an analyst at U.S. Bancorp BTIG, noted in a report to investors that the TAVR business has reached a state of stabilization.
"Looking ahead, TAVR revenue growth is expected to be driven primarily by procedure volumes; we see plenty of opportunity here with the aortic stenosis market clearly underpenetrated," Thibault said. Her analysis aligns with the company’s internal view that the market for heart valve therapies is far from saturated. Even in developed markets like the U.S. and Europe, a significant portion of the population suffering from valvular heart disease remains undiagnosed or untreated.
The stabilization of hospital staffing and the streamlining of referral pathways have also contributed to the steady growth in procedure volumes. During the earnings call, executives mentioned that the "bottlenecks" previously seen in cardiovascular departments have largely cleared, allowing for a more predictable flow of patients through the system.
Implications for the Future of Structural Heart Care
The trajectory of Edwards Lifesciences reflects a broader shift in the field of cardiology toward less invasive, catheter-based interventions. The success of the Sapien 3 platform and the emerging TMTT portfolio suggest that the age of open-chest surgery for heart valve replacement is gradually being supplanted by transcatheter technologies.
For patients, this shift means shorter hospital stays, quicker recovery times, and access to life-saving treatments that were previously unavailable to those deemed "too high-risk" for surgery. For the healthcare system, the move toward proactive management of moderate and asymptomatic disease could potentially lower long-term costs by reducing the frequency of emergency hospitalizations for heart failure.
As Edwards Lifesciences looks toward 2027, the company remains focused on expanding the clinical evidence base for its products and entering new geographic markets. With a bolstered financial forecast and a pipeline of new indications, the company is positioned to maintain its leadership in the structural heart space. The combination of the PROGRESS trial data and the modernized CMS coverage serves as a powerful tailwind, ensuring that Edwards remains at the forefront of medical innovation for years to come.
In summary, the third quarter of 2026 has been a landmark period for Edwards Lifesciences. By exceeding sales targets, raising guidance, and securing pivotal clinical and regulatory wins, the company has reinforced its status as a cornerstone of the medtech industry. The shift toward treating patients earlier in the disease cycle represents the next frontier of cardiovascular care, and Edwards appears uniquely positioned to lead that transition.
